Improved Synthesis of the Selected Serine Protease uPA Inhibitor UAMC-00050, a Lead Compound for the Treatment of Dry Eye Disease

Ceradini, Davide; Cacivkins, Pavel; Ramos-Llorca, Alba; Shubin, Kirill

doi:10.1021/acs.oprd.2c00244

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AI-assisted DOE is available today. A Latvian start up has developed an artificial intelligence-driven Design of Experiments (DOE) software called xT SAAM. , This adaptive DOE with deep learning assesses the data as it is being collected, instead of having all the experiments completed before such an assessment is performed. The result is a faster turnaround without compromising the data integrity.…”

Section: Tomorrow’s Tools (>2020)mentioning

confidence: 99%

Fluidized Bed Scale-Up for Sustainability Challenges. 1. Tomorrow’s Tools

Cocco,

Chew

2024

Ind. Eng. Chem. Res.

View full text Add to dashboard Cite

The scaling up of fluidized beds has been purposefully pursued for more than 100 years. Yet, over that time, scale-up tools have not significantly changed. Data analysis is typically a standard analysis of variances statistical exercise, perhaps reinforced with a design of experimental procedure. Flowsheeting and equipment design are based on institutional knowledge, albeit graphical user interface-based process flow models make that job more manageable. Advanced models such as computational fluid dynamics are used but often as a supplement and not a primary driver. As a result, the scale-up process for a fluidized bed can take more than 10 years. Fluidized beds remain at the forefront of the present time-critical sustainability challenges, e.g., carbon capture by particulate sorbents, methane-to-hydrogen, plastic-to-chemicals, etc. In view of the exigency toward net zero, today's scale-up efforts need to be accelerated, leveraging the advanced new tools that have become readily available. The problem is that such tools are often neglected, inadequately implemented, ineffectively resourced, and/or poorly understood. This motivated the current effort, which is targeted at reviewing how scale-up tools have evolved over the years and the promising new tools, addressing some of the barriers of these tools in the design and scale-up of fluidized beds, as well as contemplating what can be done to circumvent these barriers. As a follow up, a companion part 2 (Cocco, R. A.; Chew, J. W. Ind. Eng. Chem. Res., submitted for publication) proposes a new scale-up path leveraging the advanced tools to achieve timely implementation of the new green fluidized bed processes.

show abstract

Section: Tomorrow’s Tools (>2020)mentioning

confidence: 99%

Fluidized Bed Scale-Up for Sustainability Challenges. 1. Tomorrow’s Tools

Cocco,

Chew

2024

Ind. Eng. Chem. Res.

View full text Add to dashboard Cite

show abstract

“…AI-assisted DOEs are available today. For instance, an AI-driven DOE software, called xT SAAM, , evaluates the data in real time rather than only at the end, resulting in quicker feedback.…”

Section: Proposed New Pathway For Scale-upmentioning

confidence: 99%

Fluidized Bed Scale-Up for Sustainability Challenges. 2. New Pathway

Chew,

Cocco

2024

Ind. Eng. Chem. Res.

View full text Add to dashboard Cite

Despite more than 100 years of commercialization of wide-ranging fluidized bed reactors, scale-up tools and methods have remained quite similar. To exploit the benefits of fluidized beds for the time-critical sustainability challenges, scale-up has to be implemented quicker and better. Correspondingly, a companion Part 1 (Ind. Eng. Chem. Res. 2024, 63, 2519−2533 reviewed the evolution of the tools used in scaling up fluidized beds. Leveraging that, the current Part 2 aims to first overview the traditional pathway for scale-up and then propose a new pathway. Notably, instead of the traditional way of focusing on a linear sequence of progressively larger units, the emphasis is on the Phases of Discovery, Research, and Development, which apply the new tools consistently, as well as address risk mitigation and economics throughout. Based on an acrylonitrile case study, a Monte Carlo analysis indicates the new proposed pathway offers more promising economic feasibility, with net present value over 20 years (NPV 20 ) of $310MM higher, along with 35% and 42% reductions in start-up and break-even times, respectively. The increase in costs for incorporating modeling efforts is insignificant compared to the overall benefits with respect to time and economics.

show abstract

Improved Synthesis of the Selected Serine Protease uPA Inhibitor UAMC-00050, a Lead Compound for the Treatment of Dry Eye Disease

Cited by 2 publications

References 31 publications

Fluidized Bed Scale-Up for Sustainability Challenges. 1. Tomorrow’s Tools

Fluidized Bed Scale-Up for Sustainability Challenges. 1. Tomorrow’s Tools

Fluidized Bed Scale-Up for Sustainability Challenges. 2. New Pathway

Contact Info

Product

Resources

About